forodesine

Small moleculeexperimental

Forodesine is a transition-state analog inhibitor of purine nucleoside phosphorylase studied for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and for treatment of B-cell acute lymphocytic leukemia (B-ALL). — Wikipedia

Clinical trial activity

18 trials · 61 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Aug 1, 2001 (NCT00035022)

Timeline

2000s

Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Jan 1, 2004
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Interleukin-1 receptorANTAGONIST
IL1R1 antagonist
Binds the third immunoglobulin domain of the interleukin-1 receptor type 1 (IL-1R1) and nonselectively inhibits the activity of both forms of IL-1 (IL-1alpha and IL-1beta).
- Interleukin-1 receptor type 1 (IL1R1) ↗
Purine nucleoside phosphorylaseINHIBITOR
PNP inhibitor
Highly specific and potent transition state analog inhibitor of PNP that inhibits T-cell proliferation.
- Purine nucleoside phosphorylase (PNP) ↗

Chemistry & pharmacology

Loading structure…

SMILES

O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12

Mol. weight: 266.26 g/mol
Lipinski Ro5: 1 violation(s)
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-iminoribitol
amg108
amg 108
amg 108
amg 108
amg-108
amg-108
amg-108
bcx1777
bcx-1777
bcx-1777
bcx-1777
bcx-1777
fodosine
fodosine
forodesine
forodesine
forodesine
forodesine
forodesine
forodesine hcl
forodesine hcl
forodesine hydrochloride
forodesine hydrochloride
immh cpd
immucillin h
immucillin-h

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01776411	Phase 1/Phase 2 (Phase 2)	Jan 1, 2013	Mundipharma
NCT00742495	Phase 1/Phase 2 (Phase 2)	Mar 1, 2009	Innovative Therapies For Children with Cancer Consortium, Mundipharma
NCT00823355	Phase 1	Jan 1, 2009	Mundipharma
NCT00646165	Phase 1	Jul 1, 2008	Mundipharma
NCT00661921	Phase 2	Jun 1, 2008	Amgen
NCT00640523	Phase 2	Mar 1, 2008	BioCryst, State University of New York, Buffalo
NCT00501735	Phase 2	Jul 1, 2007	BioCryst, Case Western Reserve University, Duke University, Emory University, Gabrail Cancer Center, Louisiana State University, Monash University, Rutgers University, Stanford University, University of Alabama, Birmingham, University of Pittsburgh, University of Texas at Houston, University of Washington, University of Wisconsin, Wake Forest University, Washington University in St. Louis, Yale University
NCT00369473	Phase 2	Sep 1, 2006	Amgen
NCT00419081	Phase 2	Jul 1, 2006	Azienda Ospedaliera Antonio Cardarelli, Azienda Osperdaliera Vincenzo Cervello Divisione, BioCryst, Centro Goiano de Oncologia, CHU Hart Leveque, Complessa di Ematologia and Dir Departmento, Cornell University, Emory University, Erasmus University Rotterdam, Faculdade de Medicina do ABC, Federal University of Rio Grande do Sul, Free State University, Fundacao Hospital Amaral Carvalho, Government of Brazil, Hospital Brigadeiro, Hospital de Clinicias da UICAMP, Hospital Erasto Gaertner, Hospital Nossa Senhora da Conceicao, Hospital Santa Marcelina, Sao Paulo, Brasil, Humboldt University, Icahn School of Medicine at Mount Sinai, Instituto de Oncologia Pediatrica - GRAACC Grupo de Apoio as Adolescente e a Crianca com Cancer - UNIFESP, Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti, Istitutp di Ematologia ed Oncologia Medica, Klinika Okulistyki, Liberty Hematology and Oncology, Louisiana State University, New York Medical College, Service Clinique des Maladies du Sang, State University of New York, Buffalo, Technical University of Dresden, Tufts University, Universidade Federal do Parana, University of Alabama, Birmingham, University of California, Los Angeles, University of Chicago, University of Duesseldorf, University of Florence, University of Florida, University of Palermo, University of Regensburg, University of Rochester, University of Sao Paulo, University of Texas at Houston, Vanderbilt University
NCT00293826	Phase 2	Mar 1, 2006	Amgen
NCT00289549	Phase 2	Jun 1, 2005	BioCryst, University of Texas at Houston
NCT00110942	Phase 2	Feb 1, 2005	Amgen
NCT00098332	Phase 1	Nov 1, 2004	BioCryst
NCT00289562	Phase 1/Phase 2 (Phase 2)	Sep 1, 2004	BioCryst
NCT00095381	Phase 2	Mar 1, 2004	BioCryst
NCT00073944	Phase 1	Apr 1, 2003	BioCryst, Inveresk Research
NCT00061880	Phase 1/Phase 2 (Phase 2)	Feb 1, 2003	BioCryst, Inveresk Research
NCT00035022	Phase 1/Phase 2 (Phase 2)	Aug 1, 2001	BioCryst, University of Texas at Houston

Showing 18 of 18 trials

Page 1 / 1

Organizations

Research & Development (61)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
BioCryst	For profit	10	10	2	2001
Amgen	For profit	4	4	1	2005
Mundipharma	For profit	4	4	2	2008
University of Texas at Houston	Academic/Hospital	4	0	1	2001
Emory University	Academic/Hospital	2	0	1	2006
Inveresk Research	For profit	2	0	2	2003
Louisiana State University	Academic/Hospital	2	0	1	2006
State University of New York, Buffalo	Academic/Hospital	2	0	1	2006
University of Alabama, Birmingham	Academic/Hospital	2	0	1	2006
Azienda Ospedaliera Antonio Cardarelli	Academic/Hospital	1	0	1	2006
Azienda Osperdaliera Vincenzo Cervello Divisione	Academic/Hospital	1	0	1	2006
Case Western Reserve University	Academic/Hospital	1	0	1	2007
Centro Goiano de Oncologia	Academic/Hospital	1	0	1	2006
CHU Hart Leveque	Academic/Hospital	1	0	1	2006
Complessa di Ematologia and Dir Departmento	Academic/Hospital	1	0	1	2006
Cornell University	Academic/Hospital	1	0	1	2006
Duke University	Academic/Hospital	1	0	1	2007
Erasmus University Rotterdam	Academic/Hospital	1	0	1	2006
Faculdade de Medicina do ABC	Academic/Hospital	1	0	1	2006
Federal University of Rio Grande do Sul	Academic/Hospital	1	0	1	2006

61 organizations

Page 1 / 4